Overview
VVOS market data
Price History
VVOS price chart · 1M
- O
- 0.257600
- H
- 0.267500
- L
- 0.252600
- C
- 0.253100
- Vol
- 26,672.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.26
- Previous Close
- $0.26
- Day High
- $0.27
- Day Low
- $0.25
- 52 Week High
- $1.54
- 52 Week Low
- $0.25
- 7 Day Return
- -8.60%
- 30 Day Return
- -38.19%
- 90 Day Return
- -62.22%
- 1 Year Return
- -80.97%
- Daily Notional Volume
- $6.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 6.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -127.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.26 – $5.12 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4M · P/B 3.18 · P/S 0.20.
Company News
Vivos Therapeutics Announces 212% Rise YoY Over Most Recent Six-Week Period In Its New Obstructive Sleep Apnea Patient Referrals At Its Nevada Sleep & Airway Medicine CentersBenzinga · Aug 25, 2026, 12:47 PM
8-K filing — Vivos Therapeutics, Inc. (VVOS)SEC EDGAR · Aug 21, 2026, 9:30 PM
12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · Aug 21, 2026, 9:06 PM
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 14, 2026, 10:37 PM
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M EstimateBenzinga · Aug 14, 2026, 8:16 PM
VVOS stock has given up its prior gain. Vivos Therapeutics shares were trading higher after the company announced an expanded partnership to deploy Greenway Health’s AI-by-design Novare platform across Vivos’ clinical operations.Benzinga · Aug 11, 2026, 3:31 PM
Vivos Therapeutics shares are trading higher after the company announced an expanded partnership to deploy Greenway Health’s AI-by-design Novare platform across Vivos’ clinical operations.Benzinga · Aug 11, 2026, 2:24 PM
Vivos Therapeutics Expands Greenway Health AI Partnership, Could Create Up To $9M In Potential Annual ValueBenzinga · Aug 11, 2026, 12:48 PM
Vivos Therapeutics shares are trading lower. The company announced the receipt of a new U.S. patent and the extension of an existing patent related to its CARE sleep apnea devices.Benzinga · Aug 5, 2026, 12:47 PM
UPDATE: Vivos Therapeutics Announces USPTO Issues Patent No. 12,697,190 Was Reported August 4, 2026Benzinga · Aug 5, 2026, 12:35 PM